BR112012014320A2 - novos solvatos de metil{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo [3,4-b]piridin-3-il)pirimidin-5-il}carbamato - Google Patents

novos solvatos de metil{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo [3,4-b]piridin-3-il)pirimidin-5-il}carbamato

Info

Publication number
BR112012014320A2
BR112012014320A2 BR112012014320A BR112012014320A BR112012014320A2 BR 112012014320 A2 BR112012014320 A2 BR 112012014320A2 BR 112012014320 A BR112012014320 A BR 112012014320A BR 112012014320 A BR112012014320 A BR 112012014320A BR 112012014320 A2 BR112012014320 A2 BR 112012014320A2
Authority
BR
Brazil
Prior art keywords
fluorobenzyl
pyrazolo
diamino
solvates
pyridin
Prior art date
Application number
BR112012014320A
Other languages
English (en)
Inventor
Alfons Grunenberg
Birgit Keil
Franz-Josef Mais
Winfried Joentgen
Original Assignee
Bayer Intellectual Propertry Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Propertry Gmbh filed Critical Bayer Intellectual Propertry Gmbh
Publication of BR112012014320A2 publication Critical patent/BR112012014320A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

novos solvatos de metil{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo [3,4-b]piridin-3-il)pirimidin-5-il}carbamato. a invenção se refere a novos solvatos de metil{4,6-diamino-2-{1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il}carbamato, em particular ao hemi-solvato de etanol da fórmula(ia), a um processo para sua preparação, a medicamentos que contêm os mesmos, assim como ao seu emprego no tratamento de doenças.
BR112012014320A 2009-12-14 2010-12-13 novos solvatos de metil{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo [3,4-b]piridin-3-il)pirimidin-5-il}carbamato BR112012014320A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09179028 2009-12-14
PCT/EP2010/069457 WO2011073118A1 (de) 2009-12-14 2010-12-13 Neue solvate von methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamat

Publications (1)

Publication Number Publication Date
BR112012014320A2 true BR112012014320A2 (pt) 2016-07-05

Family

ID=43480729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014320A BR112012014320A2 (pt) 2009-12-14 2010-12-13 novos solvatos de metil{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo [3,4-b]piridin-3-il)pirimidin-5-il}carbamato

Country Status (12)

Country Link
US (1) US20120316183A1 (pt)
EP (1) EP2513101A1 (pt)
JP (1) JP2013513640A (pt)
KR (1) KR20120123270A (pt)
CN (1) CN102686588A (pt)
AU (1) AU2010333023A1 (pt)
BR (1) BR112012014320A2 (pt)
CA (1) CA2784010A1 (pt)
IL (1) IL219712A0 (pt)
MX (1) MX2012006719A (pt)
RU (1) RU2012129671A (pt)
WO (1) WO2011073118A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2901636A1 (en) 2013-02-21 2014-08-28 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
CN104327107A (zh) 2013-10-17 2015-02-04 广东东阳光药业有限公司 一种氟喹诺酮类抗菌药物的制备方法
AU2016371762A1 (en) 2015-12-14 2018-06-21 Cyclerion Therapeutics, Inc. Use of sGC stimulators for the treatment of gastrointestinal sphincter dysfunction
US20190381039A1 (en) 2016-12-13 2019-12-19 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS
BR112021000358A2 (pt) 2018-07-11 2021-04-06 Cyclerion Therapeutics, Inc. Uso de estimulantes de sgc para o tratamento de distúrbios mitocondriais

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10220570A1 (de) * 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine

Also Published As

Publication number Publication date
AU2010333023A1 (en) 2012-06-21
US20120316183A1 (en) 2012-12-13
CN102686588A (zh) 2012-09-19
CA2784010A1 (en) 2011-06-23
WO2011073118A1 (de) 2011-06-23
IL219712A0 (en) 2012-07-31
KR20120123270A (ko) 2012-11-08
EP2513101A1 (de) 2012-10-24
MX2012006719A (es) 2012-10-15
JP2013513640A (ja) 2013-04-22
RU2012129671A (ru) 2014-01-27

Similar Documents

Publication Publication Date Title
DOP2020000062A (es) Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
MX2013011781A (es) Derivados de pirrolotriazinona como inhibidores de pi3k.
CY1117667T1 (el) 3,4-διαρυλπυραζολια ως αναστολεις κινασης πρωτεϊνης
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
BR112013029862A2 (pt) derivados de piridin-2 (1h)-ona úteis como medicamentos para o tratamento de distúrbios mieloproliferativos, rejeição a transplante, doenças imunomediadas e inflamatórias
BRPI0911035B8 (pt) ativadores de pirrolidinona glicoquinase
BR112012015916A2 (pt) derivados de pirazina e seu uso no tratamento de distúrbios neurológicos
BR112013017779A2 (pt) derivados de oxazina e seu uso no tratamento de distúrbios neurológicos
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
UY30472A1 (es) Nuevos derivados de pirimidina, procesos para su preparacion composiciones farmacéuticas conteniédolos, procesos para su preparacion y aplicaciones.
CY1112429T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
BR112015007231A2 (pt) derivados de pirroltriazinona como inibidores de pi3k
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
BR112012012458A2 (pt) novas formas polimórficas de metil {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo [3,4-b] piridin-3-il] pirimidin-5-il} carbamato
BR112013025777A2 (pt) imidazopiridazinas como inibidores da quinase akt
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
BR112014002245A2 (pt) derivados de piridin-2(1h)-ona como inibidores de jak
BR112012012618A2 (pt) processo para preparação de metil {4, 6-diamino-2-[1-(2-fluorobenzil) - 1h-pirazolo [3, 4-b] piridin-3-il] pirimidin-5-il} carbamato e sua purificação para uso com substância ativa farmacêutica
CO6361926A2 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
BR112012014320A2 (pt) novos solvatos de metil{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo [3,4-b]piridin-3-il)pirimidin-5-il}carbamato
EA201491651A1 (ru) Новые соединения для лечения дислипидемии и родственных заболеваний

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]